SLC5A2 and cardiomyopathy: Both metformin and SGLT2 inhibitors activate SIRT1 and AMPK, which may explain their effect to alleviate cellular stress and ameliorate the course of experimental cardiomyopathy, benefits that are likely mediated through their actions to restore mitochondrial function, both directly and indirectly, through their actions to promote autophagy.